Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 8/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.35 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.35 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 4/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL994477 | 1.00 | FKBP1A (0.36) | FKBP1APDK1PDK2PDK3PDK4 | |
| SCHEMBL16611573 | 0.88 | FKBP1A (0.41) | FKBP1APDK1PDK2PDK3PDK4 | |
| SCHEMBL16611571 | 0.88 | FKBP1A (0.41) | FKBP1APDK1PDK2PDK3PDK4 | |
| Hydrochloric Acid SCHEMBL16611804 | 0.87 | FKBP1A (0.41) | FKBP1APDK1PDK2PDK3PDK4 | |
| Hydrochloric Acid SCHEMBL16611802 | 0.87 | FKBP1A (0.41) | FKBP1APDK1PDK2PDK3PDK4 | |
| SCHEMBL9949645 | 0.85 | FKBP1A (0.39) | FKBP1APDK1PDK2PDK3PDK4 | |
| SCHEMBL9949649 | 0.85 | FKBP1A (0.39) | FKBP1APDK1PDK2PDK3PDK4 | |
| SCHEMBL1248269 | 0.85 | ALDH1A1 (0.42) | PDK1PDK2PDK3PDK4ALDH1A1 | |
| SCHEMBL1248266 | 0.85 | ALDH1A1 (0.42) | PDK1PDK2PDK3PDK4ALDH1A1 | |
| SCHEMBL1248268 | 0.85 | ALDH1A1 (0.42) | PDK1PDK2PDK3PDK4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048528-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | NOVEXEL (FR) | 2010-02-25 | — | — | US | disclosed |
| US-20090215747-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | AVENTIS PHARMA S.A. (FR) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048528-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | BACE1, GAA, CEL | FKBP1A 2156/4885PDK1 2152/4885PDK2 2625/4885 |
| US-20090215747-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF BETA-LACTAMASES | BACE1, GAA, CEL | FKBP1A 2156/4885PDK1 2152/4885PDK2 2625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.